Wild‐type p53 enhances annexin IV gene expression in ovarian clear cell adenocarcinoma

The protein annexin IV (ANX4) is elevated specifically and characteristically in ovarian clear cell adenocarcinoma (CCA), a highly malignant histological subtype of epithelial ovarian cancer. On the basis of the hypothesis that the expression of ANX4 in CCA is regulated by a unique transcription mechanism, we explored the cis‐elements involved in CCA‐specific ANX4 expression using a luciferase reporter. We compared the transcriptional activities of the region from −1534 to +1010 relative to the ANX4 transcription start site in CCA and non‐CCA‐type cell lines, and found that two repeated binding motifs for the tumor suppressor protein, p53, in the first intron of ANX4 were involved in CCA‐specific transcriptional activity. Furthermore, chromatin immunoprecipitation showed that endogenous p53 bound to this site in CCA cell lines. Moreover, the use of short interference RNA to silence the p53 gene decreased the transcriptional activity and mRNA expression of ANX4 in CCA cell lines. Thus, the ANX4 gene is, at least in part, regulated by p53 in CCA cells. Mutations in the p53 gene were absent and levels of p53 target genes were higher in several CCA‐derived cell lines. Although the expression of ANX4 is typically low in these non‐CCA cell lines, ANX4 levels were elevated more than three‐fold by the overexpression of wild‐type but not mutant p53. Therefore, we conclude that the ANX4 gene is a direct transcriptional target of p53, and its expression is enhanced by wild‐type p53 in CCA cells.

[1]  T. Enomoto,et al.  Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin , 2009, International journal of cancer.

[2]  J. Kigawa,et al.  Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma , 2008, Cancer science.

[3]  H. Kawasaki,et al.  Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma , 2006, Proteomics.

[4]  Kathleen R. Cho,et al.  Classifications of ovarian cancer tissues by proteomic patterns , 2006, Proteomics.

[5]  Takako Yamada,et al.  Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. , 2006, Cancer letters.

[6]  S. Altmann,et al.  mRNA and 18S-RNA coapplication-reverse transcription for quantitative gene expression analysis. , 2005, Analytical biochemistry.

[7]  David P Lane,et al.  p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.

[8]  Kuang-Yu Jen,et al.  Identification of novel p53 target genes in ionizing radiation response. , 2005, Cancer research.

[9]  F. Bray,et al.  Ovarian cancer in Europe: Cross‐sectional trends in incidence and mortality in 28 countries, 1953–2000 , 2005, International journal of cancer.

[10]  C. Scharf,et al.  Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. , 2004, Cancer letters.

[11]  Patrick Dowd,et al.  The ubiquitin ligase COP1 is a critical negative regulator of p53 , 2004, Nature.

[12]  S. Moss,et al.  The annexins , 2004, Genome Biology.

[13]  Muyang Li,et al.  Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2 , 2003, Science.

[14]  Trevor Hastie,et al.  Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.

[15]  B. Kishore,et al.  Annexin A4 Reduces Water and Proton Permeability of Model Membranes but Does Not Alter Aquaporin 2–mediated Water Transport in Isolated Endosomes , 2003, The Journal of general physiology.

[16]  Guillermina Lozano,et al.  Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation , 2003, Cell.

[17]  T. Lawrence,et al.  Global Genechip Profiling to Identify Genes Responsive to p53-Induced Growth Arrest and Apoptosis in Human Lung Carcinoma Cells , 2003, Cancer biology & therapy.

[18]  T. Okai,et al.  p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. , 2003, Gynecologic oncology.

[19]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[20]  Mitsuaki Suzuki,et al.  Low Proliferation Activity May Be Associated With Chemoresistance in Clear Cell Carcinoma of the Ovary , 2002, Obstetrics and gynecology.

[21]  Mitsuaki Suzuki,et al.  Mechanisms of Cisplatin Resistance in Clear Cell Carcinoma of the Ovary , 2002, Oncology.

[22]  Chao‐Ping Yang,et al.  Infrequent p53 Gene Mutations and Lack of p53 Protein Expression in Clear Cell Sarcoma of the Kidney: Immunohistochemical Study and Mutation Analysis of p53 in Renal Tumors of Unfavorable Prognosis , 2002, Modern Pathology.

[23]  M. Saegusa,et al.  Possible associations among expression of p14ARF, p16INK4a, p21WAF1/CIP1, p27KIP1, and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas , 2001, Cancer.

[24]  K. Vousden,et al.  Regulation and function of the p53 tumor suppressor protein. , 2001, Current opinion in cell biology.

[25]  H. Ohkawa,et al.  Differential lipid specificities of the repeated domains of annexin IV. , 2001, Biochimica et biophysica acta.

[26]  Y. Hsieh,et al.  p53 mutation is infrequent in clear cell carcinoma of the ovary. , 2001, Gynecologic oncology.

[27]  M. Pierotti,et al.  p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  N. Collins,et al.  Modulation of paclitaxel resistance by annexin IV in human cancer cell lines , 2000, British Journal of Cancer.

[29]  T. Nikaido,et al.  Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas , 1999, Cancer.

[30]  D. Lane,et al.  The p53 tumour suppressor gene , 1998, The British journal of surgery.

[31]  M. Morgan,et al.  Clinical characteristics of clear cell carcinoma of the ovary. , 1998, Gynecologic oncology.

[32]  D. Meek,et al.  Multisite phosphorylation and the integration of stress signals at p53. , 1998, Cellular signalling.

[33]  G. Casey,et al.  p53 overexpression is Not an independent prognostic factor for patients with primary ovarian epithelial cancer , 1997, Cancer.

[34]  A. Børresen-Dale,et al.  TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas , 1997, The Journal of pathology.

[35]  M. Kaetzel,et al.  Inositol 3,4,5,6-Tetrakisphosphate Inhibits the Calmodulin-dependent Protein Kinase II-activated Chloride Conductance in T84 Colonic Epithelial Cells* , 1996, The Journal of Biological Chemistry.

[36]  E. Miyagi,et al.  Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. , 1995, Gynecologic oncology.

[37]  P. Sismondi,et al.  Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma , 1995, Cancer.

[38]  R. Bast,et al.  Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. , 1993, Journal of the National Cancer Institute.

[39]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[40]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[41]  Medicine,et al.  Overexpression and mutation of p53 in epithelial ovarian cancer. , 1991, Cancer research.

[42]  H. Kawasaki,et al.  Mutagenesis of longer inserts by the ligation of two PCR fragments amplified with a mutation primer. , 2009, Journal of bioscience and bioengineering.

[43]  R. Figlin,et al.  p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. , 2007, The Journal of urology.

[44]  E. Miyagi,et al.  Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. , 1997, British Journal of Cancer.